{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:47:56Z","timestamp":1793652476211,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX001458"],"award-info":[{"award-number":["BX001458"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IMMB-002-065"],"award-info":[{"award-number":["IMMB-002-065"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12026-017-8961-8","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T02:18:52Z","timestamp":1510107532000},"page":"1103-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis"],"prefix":"10.1007","volume":"65","author":[{"given":"Alexandru","family":"Tatomir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Talpos-Caia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freidrich","family":"Anselmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kruszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas","family":"Boodhoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horea","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"8961_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2990.1989.tb01231.x","volume":"15","author":"DA Compston","year":"1989","unstructured":"Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol. 1989;15:307\u201316.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"8961_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707\u201317.","journal-title":"Ann Neurol"},{"key":"8961_CR3","doi-asserted-by":"crossref","unstructured":"Breij ECW, Brink BP, Veerhuis R, Van den Berg C, Vloet R, Yan R, Dijkstra CD, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63:16\u201325.","DOI":"10.1002\/ana.21311"},{"key":"8961_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","volume":"51","author":"CA Tegla","year":"2011","unstructured":"Tegla CA, Cudrici C, Patel S, Trippe R 3rd, Rus V, Niculescu F, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51:45\u201360.","journal-title":"Immunol Res"},{"key":"8961_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/0-387-34134-X_10","volume":"586","author":"H Rus","year":"2006","unstructured":"Rus H, Cudrici C, Niculescu F. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Adv Exp Med Biol. 2006;586:139\u201351.","journal-title":"Adv Exp Med Biol"},{"key":"8961_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ana.21524","volume":"65","author":"MH Barnett","year":"2009","unstructured":"Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32\u201346.","journal-title":"Ann Neurol"},{"key":"8961_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.20016","volume":"55","author":"MH Barnett","year":"2004","unstructured":"Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55:458\u201368.","journal-title":"Ann Neurol"},{"key":"8961_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00019052-200106000-00002","volume":"14","author":"C Lucchinetti","year":"2001","unstructured":"Lucchinetti C, Bruck W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol. 2001;14:259\u201369.","journal-title":"Curr Opin Neurol"},{"key":"8961_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/2051-5960-2-53","volume":"2","author":"G Ingram","year":"2014","unstructured":"Ingram G, Loveless S, Howell OW, Hakobyan S, Dancey B, Harris CL, et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun. 2014;2:53.","journal-title":"Acta Neuropathol Commun."},{"key":"8961_CR10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4049\/jimmunol.148.3.928","volume":"148","author":"HG Rus","year":"1992","unstructured":"Rus HG, Kim LM, Niculescu FI, Shin ML. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus. J Immunol. 1992;148:928\u201333.","journal-title":"J Immunol"},{"key":"8961_CR11","doi-asserted-by":"publisher","unstructured":"Loveless S, Neal JW, Howell OW, Harding KE, Sarkies P, Evans R, et al. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathol. 2017; https:\/\/doi.org\/10.1111\/bpa.12546.","DOI":"10.1111\/bpa.12546."},{"key":"8961_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.yexmp.2011.04.006","volume":"91","author":"CA Tegla","year":"2011","unstructured":"Tegla CA, Cudrici C, Rozycka M, Soloviova K, Ito T, Singh AK, et al. C5b-9-activated, Kv1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation. Exp Mol Pathol. 2011;91:335\u201345.","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"8961_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/glia.23090","volume":"65","author":"I Michailidou","year":"2017","unstructured":"Michailidou I, Naessens DM, Hametner S, Guldenaar W, Kooi EJ, Geurts JJ, et al. Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: implication for disease pathogenesis. Glia. 2017;65(2):264\u201377.","journal-title":"Glia"},{"key":"8961_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.07.009","volume":"180","author":"H Rus","year":"2006","unstructured":"Rus H, Cudrici C, Niculescu F, Shin ML. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol. 2006;180:9\u201316.","journal-title":"J Neuroimmunol"},{"key":"8961_CR15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4049\/jimmunol.131.2.778","volume":"131","author":"WT Liu","year":"1983","unstructured":"Liu WT, Vanguri P, Shin ML. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J Immunol. 1983;131:778\u201382.","journal-title":"J Immunol"},{"key":"8961_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40478-017-0428-6","volume":"5","author":"Y Liu","year":"2017","unstructured":"Liu Y, Given KS, Harlow DE, Matschulat AM, Macklin WB, Bennett JL, et al. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun. 2017;5:25.","journal-title":"Acta Neuropathol Commun"},{"key":"8961_CR17","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.4049\/jimmunol.167.4.2305","volume":"167","author":"L Soane","year":"2001","unstructured":"Soane L, Cho HJ, Niculescu F, Rus H, Shin ML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase\/Akt pathway. J Immunol. 2001;167:2305\u201311.","journal-title":"J Immunol"},{"key":"8961_CR18","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.4049\/jimmunol.176.5.3173","volume":"176","author":"C Cudrici","year":"2006","unstructured":"Cudrici C, Niculescu F, Jensen T, Zafranskaia E, Fosbrink M, Rus V, et al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol. 2006;176:3173\u201380.","journal-title":"J Immunol"},{"key":"8961_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1177\/1352458512438238","volume":"18","author":"G Ingram","year":"2012","unstructured":"Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, et al. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler. 2012;18:1401\u201311.","journal-title":"Mult Scler"},{"key":"8961_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2016.04.003","volume":"166-167","author":"RP Lindblom","year":"2016","unstructured":"Lindblom RP, Aeinehband S, Strom M, Al Nimer F, Sandholm K, Khademi M, et al. Complement receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Clin Immunol. 2016;166-167:89\u201395.","journal-title":"Clin Immunol"},{"key":"8961_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jneuroim.2011.08.018","volume":"239","author":"JY Kwok","year":"2011","unstructured":"Kwok JY, Vaida F, Augst RM, DY Y, Singh KK. Mannose binding lectin mediated complement pathway in multiple sclerosis. J Neuroimmunol. 2011;239:98\u2013100.","journal-title":"J Neuroimmunol"},{"key":"8961_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jneuroim.2010.03.014","volume":"223","author":"G Ingram","year":"2010","unstructured":"Ingram G, Hakobyan S, Robertson NP, Morgan BP. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol. 2010;223:124\u20137.","journal-title":"J Neuroimmunol"},{"key":"8961_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1034\/j.1600-0404.2000.101002116.x","volume":"101","author":"PJ Jongen","year":"2000","unstructured":"Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand. 2000;101:116\u201321.","journal-title":"Acta Neurol Scand"},{"key":"8961_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/1352458516669002","volume":"23","author":"S Hakobyan","year":"2017","unstructured":"Hakobyan S, Luppe S, Evans DR, Harding K, Loveless S, Robertson NP, et al. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler. 2017;23:946\u201355.","journal-title":"Mult Scler"},{"key":"8961_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","volume":"274","author":"P Nytrova","year":"2014","unstructured":"Nytrova P, Potlukova E, Kemlink D, Woodhall M, Horakova D, Waters P, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014;274:185\u201391.","journal-title":"J Neuroimmunol"},{"issue":"Pt 6","key":"8961_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/brain\/awq085","volume":"133","author":"G Ingram","year":"2010","unstructured":"Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(Pt 6):1602\u201311.","journal-title":"Brain"},{"issue":"4","key":"8961_CR27","doi-asserted-by":"publisher","first-page":"e0122048","DOI":"10.1371\/journal.pone.0122048","volume":"10","author":"S Aeinehband","year":"2015","unstructured":"Aeinehband S, Lindblom RP, Al Nimer F, Vijayaraghavan S, Sandholm K, Khademi M, et al. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One. 2015;10(4):e0122048.","journal-title":"PLoS One"},{"key":"8961_CR28","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/jcb.23113","volume":"112","author":"Y Li","year":"2011","unstructured":"Li Y, Qin Z, Yang M, Qin Y, Lin C, Liu S. Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients. J Cell Biochem. 2011;112:1930\u20137.","journal-title":"J Cell Biochem"},{"key":"8961_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/sji.12132","volume":"79","author":"H Wang","year":"2014","unstructured":"Wang H, Wang K, Wang C, Qiu W, Lu Z, Hu X. Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand J Immunol. 2014;79:127\u201330.","journal-title":"Scand J Immunol"},{"key":"8961_CR30","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.4049\/jimmunol.136.12.4456","volume":"136","author":"ME Sanders","year":"1986","unstructured":"Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol. 1986;136:4456\u20139.","journal-title":"J Immunol"},{"key":"8961_CR31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1002\/jcb.23204","volume":"112","author":"G Ingram","year":"2011","unstructured":"Ingram G, Hakobyan S, Loveless S, Robertson N, Morgan BP. Complement regulator factor H in multiple sclerosis. J Cell Biochem. 2011;112:2653\u20134.","journal-title":"J Cell Biochem"},{"key":"8961_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0022-510X(98)00086-0","volume":"157","author":"F Sellebjerg","year":"1998","unstructured":"Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci. 1998;157:168\u201374.","journal-title":"J Neurol Sci"},{"key":"8961_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","volume":"134","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017;134:35\u201344.","journal-title":"Acta Neuropathol"},{"key":"8961_CR34","doi-asserted-by":"publisher","first-page":"26977","DOI":"10.1074\/jbc.273.41.26977","volume":"273","author":"TC Badea","year":"1998","unstructured":"Badea TC, Niculescu FI, Soane L, Shin ML, Rus H. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. 1998;273:26977\u201381.","journal-title":"J Biol Chem"},{"key":"8961_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1074\/jbc.M109354200","volume":"277","author":"T Badea","year":"2002","unstructured":"Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V, et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. 2002;277:502\u20138.","journal-title":"J Biol Chem"},{"key":"8961_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.yexmp.2008.12.005","volume":"86","author":"M Fosbrink","year":"2009","unstructured":"Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, Vlaicu S, et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol. 2009;86:87\u201394.","journal-title":"Exp Mol Pathol"},{"key":"8961_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.yexmp.2009.10.010","volume":"88","author":"SI Vlaicu","year":"2010","unstructured":"Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, et al. Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol. 2010;88:67\u201376.","journal-title":"Exp Mol Pathol"},{"issue":"1\u20132","key":"8961_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0165-5728(03)00089-4","volume":"138","author":"L Lopatinskaya","year":"2003","unstructured":"Lopatinskaya L, van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J Neuroimmunol. 2003;138(1\u20132):123\u201331.","journal-title":"J Neuroimmunol"},{"key":"8961_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yexmp.2012.09.005","volume":"94","author":"CA Tegla","year":"2013","unstructured":"Tegla CA, Cudrici CD, Azimzadeh P, Singh AK, Trippe R 3rd, Khan A, et al. Dual role of response gene to complement-32 in multiple sclerosis. Exp Mol Pathol. 2013;94:17\u201328.","journal-title":"Exp Mol Pathol"},{"key":"8961_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.yexmp.2015.09.007","volume":"99","author":"AM Kruszewski","year":"2015","unstructured":"Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, et al. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2015;99:498\u2013505.","journal-title":"Exp Mol Pathol"},{"key":"8961_CR41","doi-asserted-by":"crossref","first-page":"189.187","DOI":"10.4049\/jimmunol.196.Supp.189.7","volume":"196","author":"A Tatomir","year":"2016","unstructured":"Tatomir A, Cosmin T, Cudrici C, Boodhoo D, Martin A, Mekala A, et al. RGC-32 regulates TGF-\u03b2 extracellular matrix production in multiple sclerosis. J Immunol. 2016;196:189.187.","journal-title":"J Immunol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-017-8961-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-017-8961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-017-8961-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:13:53Z","timestamp":1693196033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-017-8961-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["8961"],"URL":"https:\/\/doi.org\/10.1007\/s12026-017-8961-8","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]},"assertion":[{"value":"8 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Horea Rus has received a grant from TEVA Neuroscience (CNS-2014-174). All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}